MyDosePro knowledge hub
Stay up to date on weight-loss medicines, or explore practical questions answered using clinical evidence.
34 practical guides to dosing, results, side effects, switching, costs and everyday treatment questions.
Explore Essentials →48 source-linked updates on research, clinical trials, coverage and safety.
Browse Latest News ↓Original MyDosePro explanations based on primary research, clinical trial records and government sources—not rewritten news articles.
Obstetric specialists now have updated advice for discussing weight-loss injections around conception, pregnancy and breastfeeding. Limited safety data remain central.
Primary source: October 23 reporting on the American College of Obstetricians and Gynecologists guidance
Read explanation →New subgroup analyses presented October 20 suggest substantial weight loss with investigational CagriSema across menopause stages. The 25% result is not the trial-wide average.
Primary source: Novo Nordisk: REDEFINE 1 post-hoc analyses presented at The Menopause Society 2026
Read explanation →An October update to the petrelintide trial describes participants with type 2 diabetes.
Primary source: PE primary source
Read explanation →A zenagamtide study was first posted October 6, 2026.
Primary source: ZE primary source
Read explanation →A newly posted zenagamtide trial highlights established cardiovascular disease in its eligibility criteria.
Primary source: ZE primary source
Read explanation →A post-hoc ATTAIN-1 analysis used risk models to estimate possible future disease outcomes among adults with obesity.
Primary source: Lilly ATTAIN-1 post-hoc risk analysis
Read explanation →Lilly reported detailed ACHIEVE-4 results comparing orforglipron with insulin glargine in high-risk adults with type 2 diabetes.
Primary source: Lilly ACHIEVE-4 detailed results
Read explanation →The September 29 phase 3 paper studied weekly retatrutide in adults with obesity without diabetes over 80 weeks.
Primary source: TR primary source
Read explanation →Retatrutide targets three hormone receptors: GIP, GLP-1 and glucagon.
Primary source: TR primary source
Read explanation →TRIUMPH-1 followed participants for 80 weeks, according to the published methods.
Primary source: TR primary source
Read explanation →The recently published TRIUMPH-1 report recruited adults with obesity without diabetes.
Primary source: TR primary source
Read explanation →Lilly presented an indirect comparison drawing on SURMOUNT-1 and STEP UP study data.
Primary source: Lilly indirect weight-loss comparison
Read explanation →A phase 3 trial of petrelintide for overweight or obesity and type 2 diabetes first posted September 28.
Primary source: PE primary source
Read explanation →A phase 1 record for HRS-1596 tablets was posted September 25.
Primary source: HR primary source
Read explanation →A September 23 FDA warning letter addresses unapproved and misbranded injectable semaglutide sold online.
Primary source: FD primary source
Read explanation →The LY4329090 trial record was updated September 22.
Primary source: LY primary source
Read explanation →Novo Nordisk disclosed a head-to-head diabetes trial of investigational cagrilintide plus semaglutide.
Primary source: Novo Nordisk REIMAGINE 5 and REDEFINE 9 announcement
Read explanation →Novo Nordisk provided topline Phase 3 results for investigational CagriSema in adults with excess weight.
Primary source: Novo Nordisk REIMAGINE 5 and REDEFINE 9 announcement
Read explanation →A phase 1 study of LY4329090 first appeared in the U.S. registry on September 8, 2026.
Primary source: LY primary source
Read explanation →The ClinicalTrials.gov record for ATTAIN-2 first posted study results September 4, 2026.
Primary source: OR primary source
Read explanation →ATTAIN-2 examines orforglipron in a population with type 2 diabetes.
Primary source: OR primary source
Read explanation →ATTAIN-2 recorded a results posting in September.
Primary source: OR primary source
Read explanation →CMS pharmacy guidance distinguishes eligible formulations.
Primary source: PH primary source
Read explanation →CMS sets clinical criteria for prior authorization to its GLP-1 Bridge.
Primary source: PL primary source
Read explanation →CMS describes what happens after an initial Bridge prior authorization is approved.
Primary source: PH primary source
Read explanation →CMS says the Bridge operates outside regular Part D benefit payments.
Primary source: CM primary source
Read explanation →Eli Lilly reported results for retatrutide in adults with obesity or overweight and type 2 diabetes.
Primary source: Lilly TRIUMPH-2 and TRIUMPH-3 results
Read explanation →The TRIUMPH-3 Phase 3 report assessed investigational retatrutide in severe obesity with established cardiovascular disease.
Primary source: Lilly TRIUMPH-2 and TRIUMPH-3 results
Read explanation →An analysis of two sleep-apnea trials found greater improvements in reported vitality with tirzepatide than placebo, particularly among some participants fatigued at baseline.
Primary source: SLEEP journal: SURMOUNT-OSA post-hoc patient-reported outcomes
Read explanation →CMS launched the Medicare GLP-1 Bridge demonstration July 1, 2026.
Primary source: CM primary source
Read explanation →CMS published instructions explaining how pharmacies handle eligible GLP-1 Bridge prescriptions.
Primary source: CMS Bridge pharmacy FAQ
Read explanation →Lilly presented direct oral-treatment results in people with type 2 diabetes.
Primary source: Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results
Read explanation →A Phase 3 study compared an investigational oral GLP-1 regimen with dapagliflozin in type 2 diabetes.
Primary source: Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results
Read explanation →Lilly published findings from a diabetes study involving adults already taking insulin glargine.
Primary source: Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results
Read explanation →Lilly analyzed female participants in ATTAIN studies by menopause stage.
Primary source: Lilly ATTAIN menopause subgroup analysis
Read explanation →Novo Nordisk reported a commercial milestone for oral Wegovy after its early-2026 US launch.
Primary source: Novo Nordisk Wegovy pill launch update
Read explanation →Lilly presented additional findings about knee pain in retatrutide studies at ADA 2026.
Primary source: Lilly ADA 2026 retatrutide results
Read explanation →Lilly highlighted obstructive sleep apnea measurements from studies of investigational retatrutide.
Primary source: Lilly ADA 2026 retatrutide results
Read explanation →Lilly reported a subgroup analysis of ATTAIN trials among adults aged 65 years and older.
Primary source: Lilly ATTAIN older-adult subgroup analysis
Read explanation →Novo Nordisk announced a positive CHMP opinion for a 7.2 mg Wegovy pen in the European Union.
Primary source: Novo Nordisk CHMP higher-dose Wegovy statement
Read explanation →Novo Nordisk reported a CHMP positive opinion for oral semaglutide 25 mg for weight management.
Primary source: Novo Nordisk CHMP Wegovy pill statement
Read explanation →Eli Lilly published Phase 3 topline results for investigational retatrutide in people with obesity or overweight without diabetes.
Primary source: Lilly TRIUMPH-1 phase 3 announcement
Read explanation →CMS announced plans in May for a Medicare GLP-1 Bridge beginning July 2026.
Primary source: CMS GLP-1 Bridge advance announcement
Read explanation →The FDA proposed excluding semaglutide, tirzepatide and liraglutide from its 503B bulks list.
Primary source: FDA 503B bulks list proposal
Read explanation →Lilly announced that the newly approved Foundayo tablet was becoming available through US channels.
Primary source: Lilly Foundayo US availability announcement
Read explanation →Lilly announced that the FDA approved the oral GLP-1 orforglipron as Foundayo for qualifying adults.
Primary source: Lilly Foundayo FDA-approval announcement
Read explanation →The FDA announced approval of a higher-dose 7.2 mg semaglutide injection called Wegovy HD.
Primary source: FDA Wegovy HD approval
Read explanation →Novo Nordisk published results from an open-label trial comparing CagriSema with tirzepatide.
Primary source: Novo Nordisk REDEFINE 4 announcement
Read explanation →Educational information, not medical advice. New trial registrations are research plans, not evidence of successful treatment or FDA approval.